TY - JOUR
T1 - A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon
AU - Crowell, Cameron
AU - Zhu, Ziwen
AU - Li, Yingxiang
AU - Varela, Maria L.
AU - Ostrom, Quinn
AU - Cimino, Patrick J.
AU - Patel, Sohil H.
AU - Baker, Suzanne J.
AU - Bettegowda, Chetan
AU - Noushmehr, Houtan
AU - Kleinman, Claudia L.
AU - Canty, Laura
AU - Cruzeiro, Gustavo Alencastro Veiga
AU - Nellan, Anandani
AU - Becher, Oren
AU - Davidson, Tom B.
AU - Hambardzumyan, Dolores
AU - Green, Adam
AU - Thorne, Robert
AU - Wilson, Kelli
AU - Theeler, Brett
AU - Gregory, Jason
AU - Mathen, Peter
AU - Biassou, Nadia
AU - McThenia, Sheila
AU - Erker, Craig
AU - Galvin, Robert
AU - Soldatos, Ariane
AU - Lowenstein, Pedro R.
AU - Castro, Maria G.
AU - Jackson, Sadhana
N1 - Publisher Copyright:
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Diffuse hemispheric glioma H3 G34-mutant is primarily diagnosed in adolescents/young adults. While molecular diagnostics have improved, cellular mechanisms that drive tumor progression and therapy resistance are poorly understood. Combining previous published studies with findings from the 2024 NIH G34-mutant symposium aid in summarizing translational and clinical updates on disease development, cellular repair processes, and the immune microenvironment. This collective work is meant to outline opportunities for treatment and prolonged survival.
AB - Diffuse hemispheric glioma H3 G34-mutant is primarily diagnosed in adolescents/young adults. While molecular diagnostics have improved, cellular mechanisms that drive tumor progression and therapy resistance are poorly understood. Combining previous published studies with findings from the 2024 NIH G34-mutant symposium aid in summarizing translational and clinical updates on disease development, cellular repair processes, and the immune microenvironment. This collective work is meant to outline opportunities for treatment and prolonged survival.
UR - https://www.scopus.com/pages/publications/105013336744
UR - https://www.scopus.com/pages/publications/105013336744#tab=citedBy
U2 - 10.1038/s41698-025-01070-w
DO - 10.1038/s41698-025-01070-w
M3 - Review article
C2 - 40813437
AN - SCOPUS:105013336744
SN - 2397-768X
VL - 9
JO - npj Precision Oncology
JF - npj Precision Oncology
IS - 1
M1 - 283
ER -